psoriasis/protease

BACKGROUND OF THE INVENTION Psoriasis is a chronic skin disease characterized by erythematous plaques of thickened, reddening, and scaling skin. Psoriasis affects about 2% of the population. Onset occurs most often in early adult life, but also may begin in childhood or in aged people. Severity of

TECHNICAL FIELD The present invention provides a method and pharmaceutical composition for treating and/or preventing a disease selected from the group consisting of psoriasis and squamous cell carcinoma by inhibiting expression of squamous cell carcinoma antigen (SCCA) by cells. In addition, the

CROSS REFERENCE TO RELATED APPLICATIONS The present application is a non-provisional of U.S. Provisional patent application 61/939,992, filed Feb. 14, 2014, and U.S. Provisional patent application 61/939,740, filed Feb. 14, 2014, and of U.S. Provisional patent application 61/940,019, filed Feb. 14,

BACKGROUND OF INVENTION Itch, or pruritus, is the unpleasant sensation that leads to a desire to scratch and is a common and distressing symptom in a variety of conditions and diseases. Itch also typically occurs in peripheral diseases such as allergic conjunctivitis, allergic rhinitis, hemorrhoids,

BACKGROUND OF THE INVENTION Field of the Invention This invention is generally in the field of therapeutic delivery systems, including genetically engineered probiotic and attenuated bacteria compositions and methods for providing co-expression of protease inhibitors with plasmids, phage, phagmids

CROSS REFERENCE TO RELATED APPLICATION The present application is a non-provisional of U.S. Provisional Application No. 61/764,577, filed Feb. 14, 2013, the entirety of which is expressly incorporated herein by reference. 1. BACKGROUND OF THE INVENTION 1.1. Field of the Invention This invention is

1. FIELD OF THE INVENTION This invention relates to novel compositions comprising one or more of an acid protease enzyme and an acidic buffer, the acidic buffer comprising an acid and a pharmaceutically or cosmetically acceptable carrier, useful for treating or preventing abnormal skin conditions,

FIELD OF THE INVENTION This invention relates to novel compositions comprising one or more of an acid protease enzyme and an acidic buffer, the acidic buffer comprising an acidic buffering component that can reversibly disassociate hydrogen ions and has buffering capacity at pH values below that of

The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of serine proteases. BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin.

The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of serine proteases. BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes which include elastase, chymotrypsin, cathepsin G, trypsin and thrombin.

BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes, which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin. These proteases have in common a catalytic triad consisting of Serine-195, Histidine-57 and Aspartic acid-102 (chymotrypsin numbering system). Human

The present invention relates to certain substituted oxadiazole nonpeptides, which are useful as inhibitors of serine proteases. BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes, which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin. These proteases have in

The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of serine proteases. BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin.

This application is the national stage of International Application No. PCT/IB2009/055839 filed on Dec. 18, 2009, which claims priority under 35 USC .sctn.119 of Application No. 08172480.9 filed in Europe on Dec. 19, 2008. TECHNICAL FIELD This invention relates to inhibitors of cathepsin S, and

The present invention relates to certain substituted oxadiazole nonpeptides, which are useful as inhibitors of serine proteases. BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes, which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin. These proteases have in